Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: I-131-CLR1404
Drug: dexamethasone

First Posted Date: 2014-10-30

Last Posted Date: 2023-02-22

Lead Sponsor: Cellectar Biosciences, Inc.

Target Recruit Count: 31

Registration Number: NCT02278315

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 1 locations

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab (BMS-901608)

First Posted Date: 2014-10-23

Last Posted Date: 2022-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT02272803

Locations: 🇯🇵
Local Institution, Kasama-shi, Japan

Dexamethasone and Pain Following Total Knee Arthroplasty

Phase 4

Completed

Conditions: Acute Pain
Chronic Pain

Interventions: Other: Placebo
Drug: Dexamethasone

First Posted Date: 2014-10-22

Last Posted Date: 2018-02-20

Lead Sponsor: Duke University

Target Recruit Count: 45

Registration Number: NCT02271698

Locations: 🇺🇸
DUMC, Durham, North Carolina, United States

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

Phase 3

Terminated

Conditions: Lateral Epicondylitis
DeQuervains Tenosynovitis
Trigger Finger
Inflammatory Disease
Tennis Elbow
Tenosynovitis

Interventions: Drug: Dexamethasone
Drug: Ketorolac

First Posted Date: 2014-10-17

Last Posted Date: 2020-11-02

Lead Sponsor: NYU Langone Health

Target Recruit Count: 245

Registration Number: NCT02266433

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery

Phase 3

Terminated

Conditions: Dysphagia After Anterior Cervical Decompression and Fusion of the Spine

Interventions: Other: Saline
Drug: Dexamethasone

First Posted Date: 2014-10-17

Last Posted Date: 2018-10-25

Lead Sponsor: NYU Langone Health

Target Recruit Count: 4

Registration Number: NCT02266797

Locations: 🇺🇸
Center for Musculoskeletal Care (CMC), New York, New York, United States
🇺🇸
NYU Langone Medical Center, New York, New York, United States
🇺🇸
NY Spine Institute, Westbury, New York, United States

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Malignancies
Solid Tumors
Metastatic Cancer

Interventions: Drug: azacitidine
Drug: gemcitabine
Drug: INCB052793
Drug: nab-paclitaxel
Drug: INCB039110
Drug: dexamethasone
Drug: Carfilzomib
Drug: bortezomib
Drug: lenalidomide
Drug: pomalidomide
Drug: INCB050465

First Posted Date: 2014-10-16

Last Posted Date: 2020-04-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT02265510

Locations: 🇺🇸
Site 2, Nashville, Tennessee, United States

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Malignancies

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2014-10-06

Last Posted Date: 2017-02-07

Lead Sponsor: Emory University

Target Recruit Count: 22

Registration Number: NCT02257476

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-01

Last Posted Date: 2024-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 236

Registration Number: NCT02253316

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 7 locations